FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 06/2024 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 06/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

As of the end of June 2024 we identify the following current VC trends in Europe:

  • Total Healthcare & Life Sciences funding reached EUR 4,110m.

  • Biotech received 59% of the total investment volume (EUR 2,439m) with oncology being the leading indication (50%).

  • In June, Bright Peak Therapeutics (Switzerland) secures the highest transaction volume with EUR 83m, followed by iOnctura (Switzerland) with EUR 80m and UroMems (France) with EUR 44m.

  • European Innovation Council Fund (Belgium) is the most active investor (by deal volume), followed by M&G Investments (United Kingdom) and Patient Square Capital (United States).

To access the full report, please click here.

By Mathias Klozenbücher and Johannes Link